Vericel Corp (VCEL)
46.09
-0.33
(-0.71%)
USD |
NASDAQ |
Apr 24, 16:00
46.09
0.00 (0.00%)
After-Hours: 18:35
Vericel Revenue (TTM): 197.52M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 197.52M |
September 30, 2023 | 185.21M |
June 30, 2023 | 178.18M |
March 31, 2023 | 169.31M |
December 31, 2022 | 164.36M |
September 30, 2022 | 159.26M |
June 30, 2022 | 155.22M |
March 31, 2022 | 157.69M |
December 31, 2021 | 156.18M |
September 30, 2021 | 153.82M |
June 30, 2021 | 151.57M |
March 31, 2021 | 132.07M |
December 31, 2020 | 124.18M |
September 30, 2020 | 118.34M |
June 30, 2020 | 116.58M |
March 31, 2020 | 122.72M |
December 31, 2019 | 117.85M |
September 30, 2019 | 109.80M |
June 30, 2019 | 101.78M |
March 31, 2019 | 94.64M |
December 31, 2018 | 90.86M |
September 30, 2018 | 82.87M |
June 30, 2018 | 74.65M |
March 31, 2018 | 72.59M |
December 31, 2017 | 63.92M |
Date | Value |
---|---|
September 30, 2017 | 57.10M |
June 30, 2017 | 53.77M |
March 31, 2017 | 49.64M |
December 31, 2016 | 54.38M |
September 30, 2016 | 53.28M |
June 30, 2016 | 53.66M |
March 31, 2016 | 54.43M |
December 31, 2015 | 51.17M |
September 30, 2015 | 50.45M |
June 30, 2015 | 48.80M |
March 31, 2015 | 39.64M |
December 31, 2014 | |
September 30, 2014 | |
June 30, 2014 | |
March 31, 2014 | |
December 31, 2013 | |
September 30, 2013 | |
June 30, 2013 | |
March 31, 2013 | |
December 31, 2012 | |
September 30, 2012 | |
June 30, 2012 | |
March 31, 2012 | |
December 31, 2011 | |
September 30, 2011 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
101.78M
Minimum
Jun 2019
197.52M
Maximum
Dec 2023
145.88M
Average
153.82M
Median
Sep 2021
Revenue (TTM) Benchmarks
Arbutus Biopharma Corp | 18.14M |
Chimerix Inc | 0.324M |
Karyopharm Therapeutics Inc | 146.03M |
Axsome Therapeutics Inc | 270.60M |
Y-mAbs Therapeutics Inc | 84.82M |